The Life Sciences team represented Rubius Therapeutics (NASDAQ: RUBY) in the upsized underwritten public offering of 6,896,552 shares of its common stock at a public offering price of $29.00 per share. The gross proceeds to Rubius from the offering were approximately $200 million, before deducting the underwriting discounts and commissions and other offering expenses. Rubius has granted the underwriters a 30-day option to purchase up to an additional 1,034,482 shares of its common stock.
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas.